[1] 胡盛寿,王增武.《中国心血管健康与疾病报告2022》概述[J].中国心血管病研究,2023,21(7):577-600.
[2] CAMPISI J, KAPAHI P, LITHGOW GJ, et al. From discoveries in ageing research to therapeutics for healthy ageing. Nature. 2019;571(7764):183-192.
[3] 李嘉欣,钱欣,赵俊捷,等.衰老对心脏结构和功能的影响与机制的研究[J].心脏杂志,2020,32(2):190-192,205.
[4] MESCHIARI CA, ERO OK, PAN H, et al. The impact of aging on cardiac extracellular matrix. Geroscience. 2017;39(1):7-18.
[5] YAP J, IREI J, LOZANO-GERONA J, et al. Macrophages in cardiac remodelling after myocardial infarction. Nat Rev Cardiol. 2023;20(6):373-385.
[6] HE J, WO D, MA E, et al. Huoxin pill prevents excessive inflammation and cardiac dysfunction following myocardial infarction by inhibiting adverse Wnt/beta‑catenin signaling activation. Phytomedicine. 2022; 104:154293.
[7] HE J, WO D, MA E, et al. Network pharmacology-based analysis in determining the mechanisms of Huoxin pill in protecting against myocardial infarction. Pharm Biol. 2021;59(1):1191-1202.
[8] 刘明,何宜斌,蔡炳勤.论《四圣心源》与岭南疡科流派的学术渊源[J].中国医药导报,2017,14(36):141-144.
[9] 马倩,何华.炎性衰老的分子机制及干预疗法的研究进展[J].心肺血管病杂志, 2025,44(6):660-664.
[10] 秦永生,苏俊,牟欣奕,等.血清中炎症因子与炎性衰老的相关性研究[J].广州医药,2024,55(12):1407-1413.
[11] 漆仲文,吴丹,赵俊男,等.中药治疗心血管衰老药理作用研究进展与思考[J]. 中草药,2024,55(21):7567-7574.
[12] 黄蝶,梁伟.血管衰老与老年心血管疾病相关性的研究进展[J].心血管病学进展, 2024,45(5):412-415,424.
[13] 周远,苏式兵.中药复方配伍的研究方法及其进展[J].中国实验方剂学杂志,2019, 25(23):202-208.
[14] 庞婷,麦蓝尹,陈勇,等.中药药对配伍的化学成分变化研究进展[J].中药材, 2015,38(11):2429-2434.
[15] 唐于平,束晓云,李伟霞,等.药对研究(Ⅰ):药对的形成与发展[J].中国中药杂志,2013,38(24):4185-4190.
[16] 张敏州.国医大师陈可冀中西医结合临证效验录[M].北京:人民卫生出版社,2020.
[17] 于子凯.陈可冀院士治疗常见心血管疾病临证经验[J].中西医结合心脑血管病杂志,2023,21(16): 3083-3086.
[18] 刘龙涛,陈可冀.芳香温通方药在冠心病心绞痛防治中的古今应用[J].中国中西医结合杂志,2013,33(8):1013-1017.
[19] 王玲玲,付桃芳,杜俊英,等.基于SPSS Clementine的关联规则分析在中医药数据挖掘中的应用优势和局限[J].云南中医学院学报,2016,39(6):98-102.
[20] 吴沅皞,刘维,赵文甲.血清药理学方法对药理、药效学和新药研发的贡献[J].中国组织工程研究,2018,22(24):3914-3920.
[21] 林陶秀,张文娟,张悦健,等.最佳中药含药血清浓度的筛选方法研究现状[J].中国实验方剂学杂志,2023,29(2):195-202.
[22] 张红敏,谢春光,陈世伟.含药血清体外药理试验的评价[J].中国中西医结合杂志,2004(8):741-745.
[23] ABDELLATIF M, RAINER PP, SEDEJ S, et al. Hallmarks of cardiovascular ageing. Nat Rev Cardiol. 2023;20(11):754-777.
[24] WANG H, CHEN W, CUI Y, et al. Anhydroicaritin suppresses tumor progression via the PI3K/AKT signaling pathway in hepatocellular carcinoma. Aging (Albany NY). 2023;15(15):7831.
[25] LUO TT, LU Y, YAN SK, et al. Network Pharmacology in Research of Chinese Medicine Formula: Methodology, Application and Prospective. Chin J Integr Med. 2020;26(1):72-80.
[26] 姜坤,张明雪.《金匮要略》“阳微阴弦”思想治疗胸痹心痛探析[J].辽宁中医杂志,2019,46(4):691-693.
[27] 叶康,苏立杰,高俊杰,等.芳香温通方药治疗冠心病的研究进展[J].中西医结合心脑血管病杂志,2019,17(2):204-206.
[28] 赵婉璐,潘轶,徐诗蕙,等.以附子、肉桂、干姜为例探讨走守配伍的研究进展[J].中华中医药杂志,2022,37(12):7240-7243.
[29] 黎同明,王桂香,高洁,等.附子干姜配伍温阳通脉作用的实验研究[J].中药新药与临床药理,2011,22(4):373-375.
[30] 蒲婷婷,王宇飞,周忠瑜,等.附子品质评价及影响因素研究进展[J].世界科学技术-中医药现代化,2022,24(11):4189-4198.
[31] 陈勇,王洁,杨彤,等.麝香及麝香类中成药在心力衰竭中的研究进展[J].实用中医内科杂志,2023,37(1):57-59.
[32] 刘锷,韩林涛,薛大权.瓜蒌薤白药对的研究进展[J].湖北中医药大学学报, 2014,16(6):111-114.
[33] FERRUCCI L, FABBRI E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505-522.
[34] AZEVEDO PS, POLEGATO BF, MINICUCCI MF, et al. Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment. Arquivos Brasileiros de Cardiologia. 2019; 106(1):62-69.
[35] MEHDIZADEH M, AGUILAR M, THORIN E, et al. The role of cellular senescence in cardiac disease: basic biology and clinical relevance. Nat Rev Cardiol. 2022; 19(4):250-264.
[36] BIRCH J, GIL J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 2020;34(23-24):1565-1576.
[37] OHTANI N. The roles and mechanisms of senescence-associated secretory phenotype (SASP): can it be controlled by senolysis? Inflamm Regen. 2022;42(1):11.
[38] CHEN MS, LEE RT, GARBERN JC. Senescence mechanisms and targets in the heart. Cardiovasc Res. 2022;118(5): 1173-1187.
[39] LIANG QQ, ZHANG M, ZHOU Q, et al. Muscone protects vertebral end-plate degeneration by anti-inflammatory property. Clin Orthop Relat Res. 2010; 468(6):1600-1610.
[40] DU Y, GU X, MENG H, et al. Muscone improves cardiac function in mice after myocardial infarction by alleviating cardiac macrophage-mediated chronic inflammation through inhibition of NF-κB and NLRP3 inflammasome. Am J Transl Res. 2018;10(12):4235-4246.
[41] DENG T, WEI Z, GAEL A, et al. Higenamine Improves Cardiac and Renal Fibrosis in Rats With Cardiorenal Syndrome via ASK1 Signaling Pathway. J Cardiovasc Pharmacol. 2020;75(6):535-544.
[42] FAN CL, YAO ZH, YE MN, et al. Fuziline alleviates isoproterenol-induced myocardial injury by inhibiting ROS-triggered endoplasmic reticulum stress via PERK/eIF2α/ATF4/Chop pathway. J Cell Mol Med. 2020;24(2):1332-1344.
[43] KALTSCHMIDT C, GREINER JFW, KALTSCHMIDT B. The transcription factor NF-κB in stem cells and development. Cells. 2021;10(8):2042.
[44] TILSTRA JS, CLAUSON CL, NIEDERNHOFER LJ, et al. NF-κB in aging and disease. Aging Dis. 2011;2(6):449.
[45] FAN D, TAKAWALE A, LEE J, et al. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 2012;5(1):15.
[46] MEBRATU YA, SONI S, ROSAS L, et al. The aged extracellular matrix and the profibrotic role of senescence-associated secretory phenotype. Am J Physiol Cell Physiol. 2023; 325(3):C565-C579.
|